Compare Cassava Sciences Inc (FLNA) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Boston Beer Company Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Boston Beer Company Inc trades at $180.32 (market cap $1.77B). The key difference: Boston Beer Company Inc is far larger — about 33.3× Cassava Sciences Inc's market cap, and Boston Beer Company Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SAM | |
|---|---|---|
Market Cap | $53.14M | $1.77B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $260.05 |
52-Week Low | $1.09 | $161.08 |
Enterprise Value | -$33.43M | $1.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Boston Beer Company (SAM) trades at $173.89, up 3.04% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a P/E of 22.66 and P/S of 0.94, with recent earnings beating expectations in Q3 and Q4 2025 but missing in Q1 2026. Operating cash flow remains positive at $270M for 2025, though net income margin turned negative to -3.15% in 2026 projections. Analyst consensus is 'Hold' with a $213.50 price target, representing 22.8% upside potential.
The outlook presents a mixed picture: valuation appears reasonable with solid cash generation, but profitability concerns and bearish technicals create headwinds. Key opportunities include continued 'Beyond Beer' expansion and cost-saving initiatives, while risks involve volume pressure on key brands and execution challenges in a competitive beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
